Dysregulation of IGFBPs as a result of epigenetic modifications has been identified in many tumours, such as aberrant DNA methylation of the promoter of IGFBP-2 and IGFBP-3 genes in hepatomas and breast cancers respectively [25, 26]. Here, IGFBP2 is linked to breast cancer.